Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Eaglet Corp. gets mentioned in article on abuse deterrent drugs.
https://seekingalpha.com/article/4206069-abuse-deterrent-opioids-business-answer-opioid-abuse-crisis
One of the next few quarters earnings will turn positive and this will easily be over 4 bucks again
This was $8 just 2 years ago with zero revenue.
Manipulation on the last few trading days? Very small trades trying to get price down
EGLT needs to get back over a buck and stay there to avoid a delisting
they should buy back some shares?
Sounds good to me!
It would be nice to do a share buy back to boost shareholder value
Up 36% maybe a buyout coming.
This is worth about $6.50/share ........ enterprise value
heavy buy volume today, must be news on the way?
28 million in sales mostly from the nose spray
Institutional ownership now at 19%.
I have always said, if EGLT has the only product on the market it might make some money.
It would be nice if they do ban opioid drugs to just let the safer formulations to stay on the market.
Do you have some new numbers?
the problem is that no one wants to pay premium for the pills
we will see in the next few quarters?
if they don't get close to the break even point
What other companies are selling opioids that are bound up in a non crushable compound?
who has the sole patent rights?
COLL is one
We may see .27 next week
the Oregon article said they would have exceptions.
I say extended-release
Unless of coarse, Oregon licenses magic.
They will still give 5 days out to people that just had a surgical procedure , this will be the only exception if they end up with a federal ban.
I can think of a solution to Oregon's plan
Oregon Considering Nation’s Most Dramatic Prescription Opioid Coverage Cut For Medicaid Patients With Chronic Pain
http://dailycaller.com/2018/08/15/oregon-considers-opioid-proposal/
Oregon is considering slashing prescription opioid coverage and weaning Medicaid chronic pain patients off of opioids by 2021 as part of a proposed policy that would be the most restrictive in the nation.
The Oregon Health Plan is considering a proposal that would force Medicaid patients who want prescription opioid coverage to taper their dosages to zero from 2020 to 2021. The proposal, which could be approved as early as October, would apply to patients with one or more of “five broad chronic pain conditions,” reported the Bend Bulletin.
Oregon’s state Medicaid program does not cover treatments for the five chronic pain conditions, which include fibromyalgia, chronic postprocedural pain and trauma-related chronic pain. Under the proposal, Medicaid would cover those conditions with treatments like acupuncture, physical therapy or even yoga.
However, chronic pain patients who wanted Medicaid to cover long-term opioid prescriptions would need to taper. Right now, Oregon’s Medicaid program is covering opioid prescriptions for many of those patients because state Medicaid “has no way of knowing whether those patients are being prescribed opioids for those chronic pain conditions or for covered services,” reported the Bend Bulletin.
“It is important to note that this policy would not be universal,” an Oregon Health Authority spokeswoman told STAT via email. “If doctor/patient felt that the taper was inappropriate because of the specific circumstances and comorbidities for that patient, an exception could requested and made by the plans.”
Although the state’s overdose rate was only half of the nation’s average in 2016, its doctors prescribe opioids at a rate “slightly higher” than the national average, according to 2015 numbers cited by STAT.
The state did not say how many people the proposal could affect, but 1 million Oregon residents have Medicaid, and approximately 11 percent of U.S. adults have chronic pain according to the National Institutes of Health.
Critics of the proposal say that cutting patients off from painkillers could make them turn to illegal drugs or consider suicide, reported STAT. Critics also point out that there is “little research to suggest that tapers, particularly forced tapers, improved outcomes for patients,” reported the Bend Bulletin. (RELATED: Trump Administration Health Officials Push Cheaper Off-Exchange Health Plans For Middle-Income Americans)
“What is notably missing is any review of any literature regarding the centerpiece of their proposed policy: Forced opioid taper to zero for all persons,” Dr. Stefan Kertesz, a pain and addiction specialist at the University of Alabama in Birmingham, told STAT.
although it says animals. Can EGLT get into vets?
I think this FDA press release came out an hour ago, which my explain the spike.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm617007.htm
Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new resource guide to support responsible opioid prescribing for pain management in animals
For Immediate Release
August 15, 2018
Statement
As FDA Commissioner, addressing the opioid epidemic and the misuse and abuse of these drugs remains one of my highest priorities. As we look at tackling the opioid crisis, it’s important that we take a close look at all the access points where these powerful medications can be obtained. We must also ensure that all health care professionals understand their role and responsibility in prescribing these products, and lend our support in appropriately managing them.
One such important care group is veterinarians who may prescribe them to manage pain in animals.
The FDA remains committed to addressing the epidemic on all fronts, with a significant focus on decreasing exposure to opioids and preventing new addiction by taking steps to encourage more appropriate prescribing. One of the key ways we offer support to health care providers who have a nexus to prescription opioids is encouraging them to take advantage of any available opportunity to educate themselves about the safe use of opioids. When it comes to the prescribing of these drugs in humans, we have worked carefully on developing a framework for the content for these trainings made available through the Risk Evaluation and Mitigation Strategy (REMS) program for opioid analgesics. Our training “blueprint” provides information on acute and chronic pain management; safe use of opioid analgesics or other non-opioid or non-drug treatments; as well as material on addiction medicine and opioid use disorders.
While any health care provider can take advantage of these trainings, we recognize there hasn’t been a lot of information tailored specifically for veterinary medicine. That’s why we have developed a new resource containing information and recommendations specifically for veterinarians who stock and administer opioids. Today we’re issuing important information for veterinarians to ensure they have additional context regarding the potential for people to misuse the products that they are prescribing to their animal patients.
We recognize that opioids and other pain medications have a legitimate and important role in treating pain in animals – just as they do for people. But just like the opioid medications used in humans, these drugs have potentially serious risks, not just for the animal patients, but also because of their potential to lead to addiction, abuse and overdose in humans who may divert them for their own use.
While opioids are just one part of the veterinarian’s medical arsenal for treating pain in animals, it’s important to understand the role veterinarians, who stock and administer these drugs, play in combatting the abuse and misuse of pain medications. This is especially important because the only FDA-approved opioid for use in animals (Recuvyra, a fentanyl product) is not currently marketed by the manufacturer. Carfentanil, which is 100 times more potent than fentanyl, is no longer FDA-approved for use in animals after Wildlife Laboratories withdrew the application for Wildnil this past spring. Companies are making business decisions about discontinuing the marketing of these products in the context of the current epidemic and with the goal of wanting to avoid the possibility of products being obtained or used illegally. The result is a lack of products that are FDA-approved specifically for use in animals, leaving veterinarians to prescribe products originally approved for use in humans when they determine a need for opioid pain medications for pets.
Among the recommendations we’re announcing today for veterinarians is a reminder about the importance of following all state and federal regulations on prescribing opioids to animals for pain management and how to properly safeguard and store these medications to ensure they remain in the legal supply chain.
While each state creates its own regulations for the practice of veterinary medicine within its borders, including regulations about secure storage of controlled substances like opioids, veterinarians should also follow professional standards set by the American Veterinary Medical Association (AVMA) in prescribing these products to ensure those who are working with these powerful medications understand the risks and their role in combatting this epidemic. Veterinarians are also required to be licensed by the Drug Enforcement Agency to prescribe opioids to animal patients, as are all health care providers when prescribing for use in humans. These measures are in place to help ensure the critical balance between making sure animals can be humanely treated for their pain, while also addressing the realities of the epidemic of misuse, abuse and overdose when these drugs are diverted and used illegally by humans.
The FDA is also recommending veterinarians use alternatives to opioids for pain management when appropriate; we’re educating pet owners on the safe storage and disposal of opioids; we’re advising veterinarians to develop a safety plan in the event they encounter a situation involving opioid diversion or clients seeking opioids under the guise of treating their pets; and taking steps to help veterinarians spot the signs of opioid abuse.
We’ve also provided a list of additional resources on opioid abuse; proper disposal of unused medications; advice on how to keep opioids and other medications safe in a veterinary clinic or other veterinary facility; and access to federal opioid training, among other resources.
We know that licensed veterinarians share our concerns and are committed to doing their part to ensure the appropriate use of prescription opioids. We hope the resources we’re providing today, coupled with the existing guidelines from AVMA, will assist the veterinary medical community about steps they can take when prescription opioids are part of their care plan for their animal patients.
As medical professionals, veterinarians have an opportunity to partner with the FDA and others to take on this public health crisis. We encourage them to continue to work with their clients and both local and national organizations, such as their state board of veterinary medicine and AVMA, to join in the fight against this tragic epidemic. In turn, we’re committed to continuing to support these professionals in their efforts to curb the diversion of opioids that are meant to manage animal pain.
We’re also committed to continuing our support of other health care professionals who utilize opioids while providing care for those in their communities, including making sure they have the information they need to appropriately manage and prescribe these products. Our efforts today build on the work we continue to advance on the appropriate prescribing for human patients, including our recent updates to the content included in training programs made available to all health care professionals involved in pain management.
And we remain steadfast in continuing to identify opportunities to bolster our support for the health care community. We’re continuing our work to educate all providers on appropriate prescribing practices, including significant updates to our REMS program. For the first time, our REMS add approved immediate-release opioid analgesics intended for use in an outpatient setting, in addition to the extended-release and long-acting formulations of these drugs that have been subject to a REMS since 2012. These are just some of the efforts we are undertaking. We’ll have more to announce in the coming weeks.
Working together, I believe that we can make progress in preventing new cases of addiction while ensuring appropriate and rational prescribing of opioids for human and animal patients with medical need.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
CVS could switch over safer opioid suppliers in Sept.
This one is being eyed
maybe, but CEO couldn't deliver a solution to the whole
listing compliance mess.
and (duck and hide) Arymo ER still doesn't recognize any sale dollars, oh well :-/
I am just watching this for now
back in at .301. Still worth .58
Let me guess, that would be you.
Hahaha elgt piece of crap stock
$EGLT PT Lowered to $1.50 at JMP Securities
I wouldn’t bet on it. It’ll probably start around this area and than move again. So will see lol
I mean with out news
Run up like this with our news you have to wonder lol think
Why do you think this dropped like 50% today. So many peeps lost money and got burned. Is this a real POS pump and dump stock
Where lol like I said timberrrrrr
This was a POS pump and dump stock. Lots of people lost their money and got burned today
thx real - so more equity also on the table hmm
at this point they should have better given a bullish answer
to preserver SH.
+++
oops, sorry wrong column - what a mistake to make (o8>
2Q18 $7.4M revs, net loss 'only' $11.93M, so 18% over 2Q17 and 1Q18 while half losses than of 2Q17 YoY and same as 1Q18.
Still ..
Gabellie asked if they would consider a stock sale to get market cap above nasdaq requirements. CEO only said that a number of options are on the table.
Missed that, that could hint into an equity deal which pumps up MCAP but unsure if it is helping old SH here due to dilution / share structure.
yes. YoY same $26M loss but double of 1Q18 while revs stagnating and a little less than YoY or 1Q18.
What is required here now is a lender deal or asset sales.
I didn't listen to CC, missed it. Did they talked about this (lenders or asset sales)?
Crunch time ..
- OS 2018-06-30 56.30M (10-Q PR) +3.42M since 5/10
- $35M = 62.17c for MCAP compliance
$1 bid extension is a given, but towards EOY they need the MCAP.
About the only exiting thing on the call was the potential of adding the Nasal label in October.
The CEO has big balls. Talking about acquiring or licensing other products. So he doesn't seem too concerned about cash.
yes, needs good development
The report is out, 7.4 million in revenue and a 22 cent loss!
how do you guys see this. Is this good or bad in the short term or long term. Do you see the stock rise today or tank?
Is it good or bad
Followers
|
32
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
672
|
Created
|
10/27/14
|
Type
|
Free
|
Moderators |
Enterprise Value (EV), using $99M total debt, $91M cash and 75M OS (fully diluted):
- $61M EV at 70c and
- $108M EV @ $1.33
EV-2 using $160M total liabilities, $91M cash and 75M OS (fully diluted):
- $122M EV at 70c and
- $169M EV @ $1.33
EV-3 using $99M total debt, $91M cash and 47M OS (current):
- $41M EV at 70c and
- $71M EV @ $1.33
Recent Status / Catalysts
- Arymo ER Sales Increase
- Completion of Debt Swap @ around $1.33/sh, fixing $50M mcap listing deficiency, removes going concern note
- Removal of the Debt Covenant triggered the going concern note (PR 3/23)
- $6B opioid crisis budget omnibus bill signed 3/23 instead of $2.8B
- $1 SP Listing Extension if required, RS as last resort (PR 3/23)
- 002 and Guardian Partnership / Sales - Extended Arymo ER Label in Oct '18
- Lawsuit Settlement (Arymo ER Extended Label Dispute)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |